GSK plc and LTZ Therapeutics, an immunotherapy-focused biotech company headquartered in Redwood City, California, have announced a new strategic research collaboration to accelerate the development of next-generation myeloid cell engagers (MCEs) for cancer treatment. The partnership aims to advance up to four potential first-in-class MCE therapies for both haematologic malignancies and solid tumours. As part of the agreement, GSK will hold an exclusive option to license global development and commercial rights for these pre-clinical candidates.
MCEs represent a rapidly emerging class of immuno-oncology therapies designed to harness the body’s own immune system to identify and destroy tumour cells. By engaging myeloid cells—which make up the majority of tissue-resident immune cells—MCEs offer the potential for deep and sustained tumour infiltration, along with a favourable safety profile. LTZ’s proprietary MCE platform has demonstrated encouraging pre-clinical activity across multiple tumour types. Compared with other immune-engaging modalities that may require intensive monitoring due to significant side effects, MCEs could enable safer, more accessible cancer treatment in community settings where most patients receive care.
Under the terms of the collaboration, LTZ will receive an initial payment of $50 million and may earn additional milestone payments tied to preclinical, clinical, regulatory, and commercial progress. The company will also be eligible for tiered royalties on global net sales of any commercial products emerging from the partnership.
